Study S000246

A Phase 3 Study of LY2189265 Compared to Insulin Glargine in Patients With Type 2 Diabetes Mellitus on a Sulfonylurea and/or Biguanide

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT01584232
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 361
Start: 2012-04
Primary completion: 2013-07
Lead sponsor: Eli Lilly and Company
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:LY2189265; DRUG:Insulin glargine; DRUG:Sulfonylureas (SU); DRUG:Biguanide (BG)
Results posted: TRUE
Secondary identifiers: OTHER:H9X-JE-GBDY

Registered primary outcomes

Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks [Baseline, 26 weeks]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0021268	The cost-effectiveness of dulaglutide versus insulin glargine for the treatment of type 2 diabetes mellitus in Japan. Ishii H, Journal of medical economics	2018	Other trial	PMID 29357718 DOI	cites ClinicalTrials.gov:NCT01584232
R0021009	Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies. Suzuki S, Health and quality of life outcomes	2017	Randomized trial	PMID 28606095 DOI	cites ClinicalTrials.gov:NCT01584232; registry reference DERIVED:28606095